3-flt | Vitгіria

: Describe how FLT-3 signaling drives hematopoietic cell proliferation and why mutations (like FLT3-ITD) lead to poor prognosis in acute myeloid leukemia (AML).

: Detail the signaling pathways and the impact of specific mutations. VitГіria 3-FLT

: Tabulate existing FDA-approved inhibitors and their efficacy in solid vs. liquid tumors. : Describe how FLT-3 signaling drives hematopoietic cell

: Review current inhibitors such as Sorafenib or Nintedanib , which block FLT-3 alongside other receptors like VEGFR and PDGFR to treat various cancers. VitГіria 3-FLT